相似文献
1
Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study.
Circ Heart Fail. 2013 Jul;6(4):862-8. doi: 10.1161/CIRCHEARTFAILURE.113.000394.
2
Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.
Circulation. 2015 May 19;131(20):1763-71. doi: 10.1161/CIRCULATIONAHA.114.014536. Epub 2015 Apr 14.
3
The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
Clin Exp Nephrol. 2018 Dec;22(6):1379-1386. doi: 10.1007/s10157-018-1599-6. Epub 2018 Jun 18.
4
Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies.
Circulation. 2002 Jun 4;105(22):2619-24. doi: 10.1161/01.cir.0000017502.58595.ed.
5
Xanthine oxidase inhibitors in heart failure: where do we go from here?
Circulation. 2015 May 19;131(20):1741-4. doi: 10.1161/CIRCULATIONAHA.115.016379. Epub 2015 Apr 14.
6
Associations of methyl donor and methylation inhibitor levels during anti-oxidant therapy in heart failure.
J Physiol Biochem. 2021 May;77(2):295-304. doi: 10.1007/s13105-021-00797-x. Epub 2021 Feb 17.
7
Allopurinol as a therapeutic option in cardiovascular disease.
Pharmacol Ther. 2017 Apr;172:139-150. doi: 10.1016/j.pharmthera.2016.12.004. Epub 2016 Dec 2.
8
3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout.
Biochem Pharmacol. 2013 Nov 1;86(9):1328-37. doi: 10.1016/j.bcp.2013.08.011. Epub 2013 Aug 30.
9
Heart failure, oxidative stress and allopurinol.
Monaldi Arch Chest Dis. 2005 Mar;64(1):33-7. doi: 10.4081/monaldi.2005.609.
10
Uric acid in chronic heart failure.
Semin Nephrol. 2005 Jan;25(1):61-6. doi: 10.1016/j.semnephrol.2004.09.010.
引用本文的文献
1
Biomarkers of Oxidative Stress Tethered to Cardiovascular Diseases.
Oxid Med Cell Longev. 2022 Jun 24;2022:9154295. doi: 10.1155/2022/9154295. eCollection 2022.
2
Serum Sulfhydryl Groups, Malondialdehyde, Uric Acid, and Bilirubin as Predictors of Adverse Outcome in Heart Failure Patients due to Ischemic or Nonischemic Cardiomyopathy.
Oxid Med Cell Longev. 2021 Apr 15;2021:6693405. doi: 10.1155/2021/6693405. eCollection 2021.
3
Associations of methyl donor and methylation inhibitor levels during anti-oxidant therapy in heart failure.
J Physiol Biochem. 2021 May;77(2):295-304. doi: 10.1007/s13105-021-00797-x. Epub 2021 Feb 17.
4
Pharmacological interventions for heart failure in people with chronic kidney disease.
Cochrane Database Syst Rev. 2020 Feb 27;2(2):CD012466. doi: 10.1002/14651858.CD012466.pub2.
5
Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
Circulation. 2018 Sep 11;138(11):1116-1126. doi: 10.1161/CIRCULATIONAHA.118.033992.
6
Association between smoking and gout: a meta-analysis.
Clin Rheumatol. 2018 Jul;37(7):1895-1902. doi: 10.1007/s10067-018-4118-y. Epub 2018 Apr 26.
7
CVD and Oxidative Stress.
J Clin Med. 2017 Feb 20;6(2):22. doi: 10.3390/jcm6020022.
8
Distinct risk factors of atrial fibrillation in patients with and without coronary artery disease: a cross-sectional analysis of the BOREAS-CAG Registry data.
Open Heart. 2017 Jan 16;4(1):e000573. doi: 10.1136/openhrt-2016-000573. eCollection 2017.
9
Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies.
Ther Clin Risk Manag. 2016 Jun 3;12:887-906. doi: 10.2147/TCRM.S106065. eCollection 2016.
10
Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study.
J Am Coll Cardiol. 2016 Feb 2;67(4):407-416. doi: 10.1016/j.jacc.2015.10.086.
本文引用的文献
1
Nitroso-redox imbalance affects cardiac structure and function.
J Am Coll Cardiol. 2013 Mar 5;61(9):933-5. doi: 10.1016/j.jacc.2012.12.016.
2
High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease.
J Am Coll Cardiol. 2013 Mar 5;61(9):926-32. doi: 10.1016/j.jacc.2012.09.066.
3
Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management.
Circulation. 2013 Jan 29;127(4):500-7; discussion 508. doi: 10.1161/CIRCULATIONAHA.112.120485.
4
Heart disease and stroke statistics--2013 update: a report from the American Heart Association.
Circulation. 2013 Jan 1;127(1):e6-e245. doi: 10.1161/CIR.0b013e31828124ad. Epub 2012 Dec 12.
5
Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival.
J Card Fail. 2012 Sep;18(9):694-701. doi: 10.1016/j.cardfail.2012.06.528. Epub 2012 Aug 3.
6
Effects of allopurinol on coronary microvascular and left ventricular function in patients with idiopathic dilated cardiomyopathy.
Can J Cardiol. 2012 Nov-Dec;28(6):721-7. doi: 10.1016/j.cjca.2012.04.005. Epub 2012 Jun 19.
7
Uric acid, allopurinol therapy, and mortality in patients with acute heart failure--results of the Acute HEart FAilure Database registry.
J Crit Care. 2012 Dec;27(6):737.e11-24. doi: 10.1016/j.jcrc.2012.03.011. Epub 2012 Jun 12.
8
Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts.
J Am Coll Cardiol. 2012 Feb 28;59(9):802-8. doi: 10.1016/j.jacc.2011.10.895.
9
Multiple biomarkers for risk prediction in chronic heart failure.
Circ Heart Fail. 2012 Mar 1;5(2):183-90. doi: 10.1161/CIRCHEARTFAILURE.111.965020. Epub 2012 Feb 23.
10
Allopurinol a new anti-ischemic role for an old drug.
J Am Coll Cardiol. 2011 Aug 16;58(8):829-30. doi: 10.1016/j.jacc.2011.02.072.
Zotero 插件